Acarbose plus metformin fixed-dose combination in the management of type 2 diabetes

Bibliography

• Rosak C, Mertes G. Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations. Diabetes Metab Syndr Obes 2012;5:357-67
   PubMedGoogle Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement. Endocr Pract 2013;19(Suppl 2):1-48
   Google Scholar
• Korean Diabetes Association. 2011 Clinical practice guidelines for type 2 diabetes in Korea. J Korean Diabetes Assoc 2011;12:71
   Google Scholar
• Kalra S, Sahay BK, Rao MS. Fixed dose combinations in diabetes: indian innovation, Indian pride. Indian J Endocrinol Metab 2012;16:4-5
   Google Scholar
• Blonde L, San Juan ZT. Fixed-dose combinations for treatment of type 2 diabetes mellitus. Adv Ther 2012;29:1-13
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) group. JAMA 1999;281:2005-12
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;35:1364-79
   Google Scholar
• International Diabetes Federation. 2011 guideline for management of postmeal glucose in diabetes. IDF; Brussels: 2011
   Google Scholar
• Hanefeld M. The role of acarbose in the treatment of non-insulin-dependent diabetes mellitus. J Diabetes Complications 1998;12:228-37
   PubMedGoogle Scholar
• Enc FY, Imeryuz N, Akin L, et al. Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release. Am J Physiol Gastrointest Liver Physiol 2001;281:G752-63
   PubMed Web of Science ®Google Scholar
• Joshi SR. Post-prandial carbohydrate modulation via gut-Indian perspective. J Assoc Physicians India 2010;58:665
   PubMedGoogle Scholar
• Hanefeld M, Schaper F. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits. Expert Rev Cardiovasc Ther 2008;6:153-63
   PubMedGoogle Scholar
• Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004;25:10-16
   PubMed Web of Science ®Google Scholar
• Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am J Med 1997;103:483-90
   PubMed Web of Science ®Google Scholar
• Bayer Healthcare Pharmaceutical Ltd. Data on file 2014
   Google Scholar
• Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr 2013;5:6
   PubMed Web of Science ®Google Scholar
• Scarpella JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res 2008;5:157-67
   Google Scholar
• Klachko D, Whaley-Connell A. Use of metformin in patients with kidney and cardiovascular diseases. Cardiorenal Med 2011;1:87-95
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• Kappe C, Patrone C, Holst JJ, et al. Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells. J Gastroenteol 2013;48:322-32
   Google Scholar
• Jenkins-Jones S, Currie CJ, Mukherjee J, et al. Association between first-line monotherapy with sulfonylurea versus metformin and risk of all-cause mortality [abstract #201]. EASD, Barcelona, Spain; September 2013
   Google Scholar
• Clinical Guidelines Task Force. Global guideline for type 2 diabetes. International Diabetes Federation. 2012;1-117. Available online at: www.idf.org/sites/default/files/IDF%20T2DM%20Guideline.pdf. Accessed on 17 June 2014
   Google Scholar
• Monnier L, Colette C, Dunseath GJ, et al. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007;30:263-9
   PubMed Web of Science ®Google Scholar
• Clissold SP, Acarbose EC. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1988;35:214-43
   PubMed Web of Science ®Google Scholar
• Holman R. Metformin as first choice in oral diabetes treatment: the UKPDS experience. Journ Annu Diabetol Hotel Dieu 2007;13-20
   PubMedGoogle Scholar
• Kalra S, Chadha M, Sharma SK, Unnikrishnan AG. Untapped diamonds for untamed diabetes: the alpha-glucosidase inhibitors. Indian J Endocr Metab 2014;18:138-41
   Google Scholar
• Miccoli R, Penno G, Del S. Multidrug treatment of type 2 diabetes. A challenge for compliance. Diabetes Care 2011;34(Suppl 2):s231-5
   Google Scholar
• Jayaram S, Hariharan RS, Madhavan R, et al. A prospective, parallel group, open labelled, comparative, multicentric, active controlled study to evaluate the safety, tolerability, and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes. J Assoc Physicians India 2010;58:679-87
   PubMedGoogle Scholar
• Bayer Healthcare Pharmaceuticals Ltd. Data on file; Clinical study report: Glucobay M FDC BE study 15420 (Unpublished data)
   Google Scholar
• Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994;121:928-35
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Brown A, Fischer J, et al. Efficacy and safety of acarbose in metformin treated patients with type 2 diabetes. Diabetes Care 1998;21:2050-5
   PubMed Web of Science ®Google Scholar
• Halimi S, Le Berre MA, Grange V. Efficacy and safety of acarbose add on therapy in the treatment of overweight patients with type 2 diabetes inadequately controlled with metformin: a double blind, placebo controlled study. Diabetes Res Clin Pract 2000;50:49-56
   PubMed Web of Science ®Google Scholar
• Phillips P, Karrasch J, Scott R, et al. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care 2003;26:269-73
   PubMed Web of Science ®Google Scholar
• Philip E, Sundaram ML, Das R, et al. Acarbose improves glycemic control as add-on or monotherapy in Indian type-2 diabetes: findings from the GlucoVIP multinational observational study. Indian J Endocrinol Metab 2013;17:S674-9
   PubMedGoogle Scholar
• Phung OJ, Scholle JM, Talwar M, et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010;303:1410-18
   PubMed Web of Science ®Google Scholar
• Melikian C, White TJ, Vanderplas A, et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002;24:460-7
   PubMed Web of Science ®Google Scholar
• Wang JS, Huang CN, Hung YJ, et al. Acarbose plus metformin fixed-dose combination outperforms acarbose monotherapy for type 2 diabetes. Diabetes Res Clin Pract 2013;102:16-24
   PubMed Web of Science ®Google Scholar
• Bayer Healthcare Pharmaceuticals Ltd. Data on file. Clinical study report (PH37466): Glucobay M FDC phase IV study 2013 (unpublished data)
   Google Scholar